The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
On May 13, ImmunityBio faced a securities class action lawsuit after the FDA issued a warning regarding misleading efficacy claims for its product Anktiva. The news caused IBRX shares to plunge by 21%, resulting in an approximate loss of $2 billion in market capitalization.